1. Home
  2. FLGC vs LYRA Comparison

FLGC vs LYRA Comparison

Compare FLGC & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLGC
  • LYRA
  • Stock Information
  • Founded
  • FLGC 2019
  • LYRA 2005
  • Country
  • FLGC United States
  • LYRA United States
  • Employees
  • FLGC N/A
  • LYRA N/A
  • Industry
  • FLGC Biotechnology: Pharmaceutical Preparations
  • LYRA Medical/Dental Instruments
  • Sector
  • FLGC Health Care
  • LYRA Health Care
  • Exchange
  • FLGC Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • FLGC 13.5M
  • LYRA 11.3M
  • IPO Year
  • FLGC 2021
  • LYRA 2020
  • Fundamental
  • Price
  • FLGC $18.64
  • LYRA $7.42
  • Analyst Decision
  • FLGC Strong Buy
  • LYRA Hold
  • Analyst Count
  • FLGC 1
  • LYRA 1
  • Target Price
  • FLGC $156.00
  • LYRA $16.00
  • AVG Volume (30 Days)
  • FLGC 106.5K
  • LYRA 32.2K
  • Earning Date
  • FLGC 11-12-2025
  • LYRA 11-11-2025
  • Dividend Yield
  • FLGC N/A
  • LYRA N/A
  • EPS Growth
  • FLGC N/A
  • LYRA N/A
  • EPS
  • FLGC N/A
  • LYRA N/A
  • Revenue
  • FLGC $52,373,000.00
  • LYRA $770,000.00
  • Revenue This Year
  • FLGC N/A
  • LYRA N/A
  • Revenue Next Year
  • FLGC $10.22
  • LYRA $123.83
  • P/E Ratio
  • FLGC N/A
  • LYRA N/A
  • Revenue Growth
  • FLGC N/A
  • LYRA N/A
  • 52 Week Low
  • FLGC $15.15
  • LYRA $3.81
  • 52 Week High
  • FLGC $82.29
  • LYRA $37.50
  • Technical
  • Relative Strength Index (RSI)
  • FLGC 45.47
  • LYRA 58.23
  • Support Level
  • FLGC $17.52
  • LYRA $6.55
  • Resistance Level
  • FLGC $20.18
  • LYRA $8.75
  • Average True Range (ATR)
  • FLGC 4.33
  • LYRA 0.56
  • MACD
  • FLGC -1.14
  • LYRA 0.18
  • Stochastic Oscillator
  • FLGC 5.95
  • LYRA 52.04

About FLGC Flora Growth Corp.

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: